EYLEA, (aflibercept) Injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, NDC 61755-005-01

Recall Insight

This FDA Drug action (record #D-0479-2024) was formally reported on May 8, 2024, with the manufacturer initiating the action on April 23, 2024. It is classified under Moderate severity (Class II), with a current status of Terminated. Regeneron Pharmaceuticals Inc is listed as the recalling firm, operating out of Tarrytown, NY. Federal records indicate 251,504 syringes units are affected, a scale large enough to require multi-state distribution tracking.

The documented reason for this recall is: Lack of Assurance of Sterility: Complaints of syringe breakage Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 2 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.